Back to Browse Journals » Drug Design, Development and Therapy » Volume 2

Development and targeted use of nilotinib in chronic myeloid leukemia

Authors Carmen Fava, Hagop Kantarjian, Jorge Cortes, Elias Jabbour

Published Date November 2008 Volume 2008:2 Pages 233—243

DOI http://dx.doi.org/10.2147/DDDT.S3181

Published 10 November 2008

Carmen Fava, Hagop Kantarjian, Jorge Cortes, Elias Jabbour

Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA

Abstract: The development of imatinib has resulted in sustained hematologic and cytogenetic remissions in all phases of chronic myeloid leukemia (CML). Despite the high efficacy, relapses have been observed and are much more prevalent in patients with advanced disease. The most common mechanism of acquired resistance has been traced to Bcr-Abl kinase domain mutations. Several strategies have been developed to overcome the problem of imatinib resistance, including imatinib dose escalation, novel targeted agents and combination treatments. A second generation of tyrosine kinase inhibitors was developed, which displays increased potency towards Bcr-Abl and is able to target the majority of CML mutant clones. Nilotinib (Tasigna®, AMN107, Novartis) is a close analog of imatinib with approximately 20-fold higher potency for BCR-ABL kinase inhibition. Preclinical and clinical investigations demonstrate that nilotinib effectively overcomes imatinib resistance, and has induced high rates of hematologic and cytogenetic responses in CML post imatinib failure, with a good tolerance. Nilotinib has been approved for CML patients in chronic and accelerated phases, post imatinib failure.

Keywords: nilotinib, imatinib-resistance, imatinib-intolerance, CML

Download Article [PDF] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

Other article by this author:

Nilotinib for the treatment of chronic myeloid leukemia: An evidence-based review

Elias Jabbour, Jorge Cortes, Hagop Kantarjian

Core Evidence 2009, 4:207-213

Published Date: 5 October 2009

Readers of this article also read:

Inhibition of A/Human/Hubei/3/2005 (H3N2) influenza virus infection by silver nanoparticles in vitro and in vivo [Corrigendum]

Xiang DX, Zheng Y, Duan W, Li XJ, Yin JJ, Shigdar S, O'Connor ML, Marappan M, Zhao XJ, Miao YQ, Xiang B, Zheng CL

International Journal of Nanomedicine 2013, 8:4703-4704

Published Date: 5 December 2013

Vincristine sulfate liposomal injection for acute lymphoblastic leukemia [Corrigendum]

Soosay Raj TA, Smith AM, Moore AS

International Journal of Nanomedicine 2013, 8:4705-4706

Published Date: 5 December 2013

Antiviral activity of mycosynthesized silver nanoparticles against herpes simplex virus and human parainfluenza virus type 3

Gaikwad S, Ingle A, Gade A, Rai M, Falanga A, Incoronato N, Russo L, Galdiero S, Galdiero M

International Journal of Nanomedicine 2013, 8:4303-4314

Published Date: 6 November 2013

Drug-eluting scaffold to deliver chemotherapeutic medication for management of pancreatic cancer after surgery

Zhan Q, Shen B, Deng X, Chen H, Jin J, Zhang X, Peng C, Li H

International Journal of Nanomedicine 2013, 8:2465-2472

Published Date: 11 July 2013

Tat peptide-decorated gelatin-siloxane nanoparticles for delivery of CGRP transgene in treatment of cerebral vasospasm [Corrigendum]

Tian XH, Wang ZG, Meng H, Wang YH, Feng W, Wei F, Huang ZC, Lin XN, Ren L

International Journal of Nanomedicine 2013, 8:2129-2130

Published Date: 13 June 2013

Development of biodegradable methylprednisolone microparticles for treatment of articular pathology using a spray-drying technique

Tobar-Grande B, Godoy R, Bustos P, von Plessing C, Fattal E, Tsapis N, Olave C, Gómez-Gaete C

International Journal of Nanomedicine 2013, 8:2065-2076

Published Date: 27 May 2013

Wound-healing effect of micronized sacchachitin (mSC) nanogel on corneal epithelium

Chen RN, Lee LW, Chen LC, Ho HO, Lui SC, Sheu MT, Su CH

International Journal of Nanomedicine 2012, 7:4697-4706

Published Date: 28 August 2012

Aminopropyltriethoxysilane-mediated surface functionalization of hydroxyapatite nanoparticles: synthesis, characterization, and in vitro toxicity assay

Wang S, Wen S, Shen M, Guo R, Cao X, Wang J, Shi X

International Journal of Nanomedicine 2011, 6:3449-3459

Published Date: 20 December 2011

Development of enteric submicron particle formulation of papain for oral delivery

Sharma M, Sharma V, Panda AK, Majumdar DK

International Journal of Nanomedicine 2011, 6:2097-2111

Published Date: 23 September 2011